|
業務類別
|
Biotechnology |
|
業務概覽
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
| 公司地址
| 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618 |
| 電話號碼
| +1 949 409-3700 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cgoncology.com |
| 員工數量
| 142 |
| Mr. Arthur Kuan |
Chairman of the Board and Chief Executive Officer |
美元 653.49K |
27/02/2026 |
| Mr. Joshua F. Patterson |
General Counsel and Chief Compliance Officer |
-- |
10/01/2025 |
| Dr. Vijay Kasturi, M.D. |
Chief Medical Officer |
-- |
25/04/2025 |
| Mr. Ambaw Bellete |
President and Chief Operating Officer |
美元 511.94K |
25/04/2025 |
| Mr. James M. DeTore |
Interim Principal Financial and Accounting Officer |
-- |
27/02/2026 |
|
|
| Mr. Victor Tong, Jr |
Independent Director |
27/02/2026 |
| Mr. Arthur Kuan |
Chairman of the Board and Chief Executive Officer |
27/02/2026 |
| Dr. Brian Liu, M.D. |
Independent Director |
27/02/2026 |
| Ms. Susan E. Graf |
Independent Director |
27/02/2026 |
| Dr. Leonard E. Post, PhD |
Lead Independent Director |
27/02/2026 |
| Ms. Christina Rossi, M.B.A. |
Director |
27/02/2026 |
| Dr. James J. Mule |
Independent Director |
27/02/2026 |
|
|
|
|
